Hello everyone and welcome to Sounds of Science.

A series of podcasts hosted by Yukope, a European trade body representing small and mid-sized companies active in health technologies.

My name is Victor Martens. I'm the Government Affairs Manager at Yukope and lead our work on ATMPs, as well as the guest

host for this podcast. Before moving forward, if you like this sort of content, please consider

subscribing to our channel for more and following us on Twitter and LinkedIn, stay up to date

on all the latest news and initiatives within the UKIP world. On today's episode, we'll be exploring

the topic of advanced therapy medicinal products or ATMPs. ATMPs have been receiving significantly

more attention in recent years, as a growing number of them come to market. All ATMPs have been

approved in the EU thus far are meant for rare diseases and orphan

indications. But if we look into what's in the pipeline, we'll see that ATMPs are under

development for non-rare chronic conditions as well. As potentially one-off transformative

treatments, these therapies are different from many others currently available or in development.

However, much like all

other therapies, ATMPs will be impacted by the ongoing review of the general pharmaceutical legislation

and in many cases, review of the OMP regulation as well. Beyond the legislative and regulatory framework,

interesting developments are also taking place with regard to HTA and pricing

reimbursement. This combination of scientific progress and legislative development will have long-term

implications for ATMPs and the competitiveness of the EU. Suffice to say, there is a lot happening

when it comes to ATMPs. And with the help of today's guests, I hope we can start to unpack a few of these discussions

and possibly look into the future as well.

Let's get started.

We're joined today with a familiar face, Alexander Nutz, the Secretary General of Yukope.

...